Oppenheimer analyst Cheng Li maintained a Buy rating on Vaxart (VXRT – Research Report) today and set a price target of $4.00. The company’s ...

Nasdaq (NASDAQ:NDAQ – Get Free Report) had its price objective reduced by research analysts at Barclays from $97.00 to $96.00 in a research note issued to investors on Monday,Benzinga reports. The ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 22.42% ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

While the rest of the world battles to make ends meet, the Forbes billionaires all increased their wealth during the past ...

Hollywood’s awards season has all but come to a rare halt as the wildfires continue to disrupt life and work in the Los ...

The US elections in November stirred up more than just political anxiety: Volatility fueled by the vote, combined with global ...

As previously reported, Oppenheimer analyst Bryan Blair upgraded A.O. Smith (AOS) to Outperform from Perform with an $88 price target given the ...

Financial-services firm Oppenheimer upgrades A.O. Smith (AOS) to Outperform, citing undervaluation and potential for profit growth.

Oppenheimer raised its price target on Snowflake ( SNOW, Financial) from $180 to $200 on Monday while retaining an " ...